Successful completion of Retail Entitlement Offer

Radiopharm Theranostics Limited (ASX:RAD, RAD or the Company), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the successful completion of the retail component of the fully underwritten 1 for 3.55 prorata accelerated non-renounceable entitlement offer (Entitlement Offer) announced by the Company on 19 October 2022. New fully paid shares under the Entitlement Offer (New Shares) will be issued at a price of $0.14, together with 1 free attaching option for every 1 New Share issued, each with an exercise price of $0.20 and exercisable on or before 30 November 2026 (New Options).

Retail Entitlement Offer
The retail component of the Entitlement Offer (Retail Entitlement Offer) closed at 5:00pm (Sydney time) on Friday, 18 November 2022, raising gross proceeds of approximately Si.2 million. Eligible retail shareholders took up 8,705,317 New Shares.
23,367,918 New Shares not subscribed for under the Retail Entitlement Offer (Shortfall Shares) will be subscribed for by Bell Potter

Securities Limited (Underwriter) or sub-underwriters, in accordance with the underwriting agreement between the Company and the Underwriter dated 20 October 2022.

Completion of the Retail Entitlement Offer represents the final stage of RAD`s approximately $10 million (before costs) Entitlement Offer. The institutional component of the Entitlement Offer (Institutional Entitlement Offer) attracted strong support and was successfully completed on Thursday, 20 October 2022, raising gross proceeds of approximately $5.5m.

The New Shares to be issued under the Retail Entitlement Offer will rank equally with existing RAD fully paid ordinary shares in all respects. New Shares and New Options under the Retail Entitlement Offer and Shortfall Offer, and New Options under the Institutional Entitlement Offer, are expected to be issued on Friday 25 November 2022 and commence normal trading on the ASX on Monday, 28 November 2022.